Adverse Event Management of Oral Mucositis in Patients with Breast Cancer

Breast care

Sabine Seiler¹  Sibylle Loibl¹  Jens Kosse¹  Christian Jackisch¹ 

[1]aDepartment of Obstetrics and Gynaecology, Breast Cancer Center, Offenbach, Germany

关键词: Oral mucositis;    Disease management;    Breast cancer;    Chemotherapy;    Molecular targeted therapy;   

DOI  :  10.1159/000366246

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Oral mucositis (OM) is a clinically important and frequent adverse event (AE) associated with cancer treatment with conventional chemotherapy as well as new targeted agents. Incidence and severity of OM vary from treatment to treatment and from patient to patient. The pathogenesis of chemotherapy-induced OM can be divided into 5 phases. OM induced by targeted therapies differs among other things in appearance, course, concomitant AEs and toxicity, and thus could be perceived as an entity distinct from chemotherapy-induced OM with an innate pathogenic mechanism. OM has a severe impact on a patient's quality of life (QoL) by causing complications such as pain and discomfort. Even more important are associated restrictions in nutrition and hydration. Thus, the efficacy of cancer therapy might be impaired due to the necessity of dose delays and dose reductions. Numerous preventive and therapeutic approaches have been evaluated, but currently no single agent has changed the standard of care in preventing and treating OM. Thus, the current management has evolved from clinical experience rather than clinical evidence. This article will review the AE ‘OM’ induced by breast cancer treatment with chemotherapy and targeted agents in order to provide practical guidance for management and prevention.

【 授权许可】

Unknown